Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (121-130 of 165) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyPaul E Sax, Camlin Tierney, Ann C Collier, et al.
Leukemia & Lymphoma|September 24, 1999
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG)R M Lowenthal, K F Bradstock, J P Matthews, et al.
Journal of Virology|April 29, 2011
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitorsJ Gerardo García-Lerma, Wutyi Aung, Mian-er Cong, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPatricia M Flynn, Mark Mirochnick, David E Shapiro, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2024
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084Mark A Marzinke, Kelong Han, Brett Hanscom, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
The Journal of Infectious Diseases|November 8, 2025
Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083Brett Hanscom, Mark A Marzinke, Xinnong Li, et al.
Microbiology Spectrum|July 9, 2024
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxisJessica M Fogel, Estelle Piwowar-Manning, Amber Moser, et al.
JMIR Research Protocols|February 4, 2020
Testing the Effectiveness and Cost-Effectiveness of a Combination HIV Prevention Intervention Among Young Cisgender Men Who Have Sex With Men and Transgender Women Who Sell or Exchange Sex in Thailand: Protocol for the Combination Prevention Effectiveness StudyAndrea L Wirtz, Brian Wilson Weir, Sandra Hsu Hnin Mon, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIVKristina M Brooks, Jeremiah D Momper, Mauricio Pinilla, et al.
Pageof 17

Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|December 3, 2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyPaul E Sax, Camlin Tierney, Ann C Collier, et al.
Leukemia & Lymphoma|September 24, 1999
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG)R M Lowenthal, K F Bradstock, J P Matthews, et al.
Journal of Virology|April 29, 2011
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitorsJ Gerardo García-Lerma, Wutyi Aung, Mian-er Cong, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPatricia M Flynn, Mark Mirochnick, David E Shapiro, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2024
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084Mark A Marzinke, Kelong Han, Brett Hanscom, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
The Journal of Infectious Diseases|November 8, 2025
Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083Brett Hanscom, Mark A Marzinke, Xinnong Li, et al.
Microbiology Spectrum|July 9, 2024
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxisJessica M Fogel, Estelle Piwowar-Manning, Amber Moser, et al.
JMIR Research Protocols|February 4, 2020
Testing the Effectiveness and Cost-Effectiveness of a Combination HIV Prevention Intervention Among Young Cisgender Men Who Have Sex With Men and Transgender Women Who Sell or Exchange Sex in Thailand: Protocol for the Combination Prevention Effectiveness StudyAndrea L Wirtz, Brian Wilson Weir, Sandra Hsu Hnin Mon, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIVKristina M Brooks, Jeremiah D Momper, Mauricio Pinilla, et al.
Pageof 17